Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical OncologyMILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations on several of its lead programs at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, including updated data for its EIK1001 trial in non-small cell lung cancer (NSCLC) and its highly selective PARP1 inhibitor EIK1003.
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 TrialMAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”).
KIAA International LLC Expands Global Leadership with Senior Corporate General Counsel Ms Jagdeep Kaur Joining as Principal Legal AdvisorNew Delhi, India, May 30, 2026 (GLOBE NEWSWIRE) -- (New Delhi, India) KIAA International LLC, the international arm of KIAA LLP, has strengthened its global leadership with the appointment of senior aviation legal expert Ms. Jagdeep Kaur as Principal Legal Advisor.
ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026Chicago, Illinois, May 30, 2026 –– ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced encouraging Health-Related Quality of Life (HRQoL) data from its Phase 3 COMPETE trial in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The data showed favorable and durable quality of life outcomes for patients receiving non-carrier-added (n.c.a.) ¹⁷⁷Lu-edotreotide (also known as ITM-11 or ¹⁷⁷Lu-edotreotide) compared to everolimus, a systemic standard of care treatment. The data were presented by Jaume Capdevila, MD, PhD, study investigator and senior medical oncologist at Vall d'Hebron University Hospital, Barcelona, Spain in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 29 - June 2, 2026 in Chicago, Illinois.“For patients with GEP-NETs, treatment decisions are not only about preventing disease progression, but also about preserving daily functioning and quality of life,” said Jaume Capdevila, MD, PhD, study investigator and senior medical oncologist at Vall d'Hebron University Hospital, Barcelona, Spain. “The COMPETE data suggest more favorable patient-reported outcomes with ¹⁷⁷Lu-edotreotide compared with everolimus, including a longer median time to deterioration in quality of life. Together with the previously reported efficacy results, these findings add important patient-centered evidence to inform treatment discussions.”The quality of life analyses included 309 patients (¹⁷⁷Lu-edotreotide, n=207; everolimus, n=102). More than 85% of patients completed the two validated EORTC QLQ questionnaires1 throughout the study: the 30-item QLQ-C30 and the 21-item QLQ-GI.NET21. Both surveys use standardized 0-100 scales to assess overall health, physical and social functioning, and GEP-NET symptom burden. Patients completed questionnaires at baseline, monthly in year one, and every three months thereafter.Key QoL Findings:
World Vape Day 2026: One Switch – Everyone WinsBRUSSELS, May 30, 2026 (GLOBE NEWSWIRE) -- Today, vapers, former smokers, and harm reduction advocates mark World Vape Day 2026. The theme this year is One Switch – Everyone Wins. It is not a slogan. It is what the data shows.
Momcozy Launches Plus Baby Wipes Built for Every “Messy Milestone”: 99% Purified Water, 8″ × 8″, Independently Certified by IntertekDesigned around the “Bring On The Mess” philosophy, the new wipes are larger than most leading brands by sheet dimensions, formulated with 99% purified water and coconut extract, and independently tested for safety by Intertek
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual MeetingHouston, Texas and Tuebingen, Germany, May 30, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. One-time infusion of IMA203CD8 demonstrated meaningful clinical activity across different tumor types as well as manageable tolerability. The broad expression of PRAME in more than 50 cancers further supports the continued development of IMA203CD8 in multiple PRAME-positive solid tumors.
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingWOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (
NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting.
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. ASCO takes place May 29-June 2 in Chicago, and SNMMI May 30-June 2 in Los Angeles.
Mikey Moran Launches GLZD, Combining Skincare and Fragrance Into Men’s Grooming RoutineAtlanta, GA, May 30, 2026 (GLOBE NEWSWIRE) -- Beauty entrepreneur Mikey Moran has officially launched GLZD, a new men’s grooming brand introducing “body glaze”—a water-free product category designed to combine skincare, fragrance, and skin finish into a single daily routine.
National Nursing Organizations File Nurse-Forward Lawsuit Against the Department of Education Over Professional Degree DesignationTen national organizations file suit challenging exclusion of post-baccalaureate nursing degrees from higher federal graduate loan borrowing limits
MZTI INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving The Marzetti CompanyNEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of The Marzetti Company (“Marzetti” or the “Company”) (
NASDAQ:MZTI) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
BRCB INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Black Rock Coffee Bar, Inc.NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Black Rock Coffee Bar, Inc. (“Black Rock Coffee” or the “Company”) (
NASDAQ:BRCB) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
VERI SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Veritone, Inc. Investors - Contact Kirby McInerney LLP by July 20, 2026NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Veritone, Inc. (“Veritone” or the “Company”) (
NASDAQ:VERI) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
EMBC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Embecta Corp.NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (
NASDAQ:EMBC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
National Nursing Organizations File Nurse-Forward Lawsuit Against the Department of Education Over Professional Degree DesignationEleven national organizations file suit challenging exclusion of post-baccalaureate nursing degrees from higher federal graduate loan borrowing limits
A New Chapter Is Emerging in Pakistan-China RelationsISLAMABAD, May 30, 2026 (GLOBE NEWSWIRE) -- The Ministry of Information and Broadcasting (MoIB) is responsible for promoting and managing the official narrative surrounding Prime Minister Shehbaz Sharif's visit to China, which celebrates the 75th anniversary of diplomatic relations.
Fairfax Completes Sale of Portion of its Interest in Poseidon Corp.TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (TSX: FFH and FFH.U) announced today that it, together with certain of its affiliates (collectively, “Fairfax”), has completed the previously announced sale of an aggregate of 67,618,981 common shares (the “Shares”) of Poseidon Corp. (“Poseidon”), the holding company that owns Seaspan Corporation, at a price of US$28.30 per share, for aggregate proceeds of approximately US$1.91 billion and a pre-tax realized gain of approximately US$837 million.
FRO - Grant of synthetic optionsFrontline plc ("Frontline" or the "Company") hereby announces that 276,895 synthetic options have today been granted to management and employees of the Company. The synthetic options will have a five-year term expiring May 29, 2031, and will vest over a three-year vesting period as follows:
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesSalt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (
NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).
Crescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 16,950 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on May 28, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
Notice of Settlement of Shareholder Derivative ActionsNEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (
NASDAQ: OLPX) ("OLAPLEX" or the "Company") today released the following pursuant to an Order of the U.S. District Court for the Central District of California.
Morgan & Morgan Announces "Grow or Die" Conference to Empower Next Generation of Law Firm LeadersLAS VEGAS, May 29, 2026 (GLOBE NEWSWIRE) -- John Morgan, founder of America’s largest injury law firm, has announced a one-of-a-kind conference taking place on June 9–10, 2026, at the Wynn Encore in Las Vegas presented by EvenUp.
Clip Money Inc. Reports First Quarter 2026 ResultsTORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Clip Money Inc. (TSX-V: CLIP) (“Clip Money” or the “Company”), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce its financial results for the three months ended March 31, 2026. The Company reported continued revenue growth in the first quarter of 2026, up 81% from Q1 2025, while cost of revenues were up only 36% during the same time period, maintaining high operating leverage into the new year.
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA NephropathySAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101. The data are expected to define the dosing strategy and further characterize JADE101’s clinical profile as a potentially differentiated, disease-modifying anti–A Proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN).
Arvinas to Present at Jefferies Global Healthcare ConferenceNEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of May 28, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Steakholder Foods Ltd. Announces Warrant Exercise for $1.1 Million in Gross ProceedsRehovot, Israel, May 29, 2026 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH) (“Steakholder Foods” or the “Company”), a leading innovator in alternative proteins and 3D printing technologies, today announced the entry into the definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 892,854 of the Company’s American Depository Shares (“ADSs”), each representing four thousand (4,000) ordinary shares of the Company, originally issued by the Company on October 1, 2025, each having an original exercise price of $5.00 per ADS, at a reduced exercise price of $1.25 per ADS. In addition, the Company will issue new warrants, as described below. The closing of the warrant exercise transaction is expected to occur on or about June 1, 2026, subject to the satisfaction of customary closing conditions.
Flutter Entertainment PLC: Results of Annual General Meeting 2026NEW YORK and DUBLIN and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- The Company announces that the following resolutions were put forward at its Annual General Meeting (“AGM”) held on May 29, 2026.
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular EdemaZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema (DME).
CFP Board Promotes Public Trust With 4 ActionsUpholding Ethical Standards in a Thriving Network of Over 109,000 CFP® Professionals
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalDANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.
FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer DrugsStreamlined approach could reduce time and cost to bring new cancer drugs into human trials
The Heat Came Early and the Grid Wasn’t Ready. Jackery Urges Families to Prepare for a Summer of Power UncertaintyAs a historic May heat wave triggers grid emergencies from DC to Philadelphia, and as AI data centers quietly reshape America’s grid, families are already feeling it. Here’s how to take back control before the heat peaks
GLOBAL Down Syndrome Foundation Celebrates Historic Bipartisan Advancement of the DeOndra Dixon INCLUDE Project ActHouse Energy & Commerce Committee Unanimously Advances Landmark Legislation as Congressional Leaders Honor DeOndra Dixon, John J. Sie, Michelle Sie Whitten, and GLOBAL's Decades of Advocacy
POET Technologies, Inc. Investors Have Until June 29th to Contact Bragar Eagel & Squire, P.C. To Seek Lead Plaintiff RoleBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In POET To Contact Him Directly To Discuss Their Options
SES AI LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Urges SES AI Corporation Investors with Significant Losses to Contact the Firm Before June 26thBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In SES To Contact Him Directly To Discuss Their Options
Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain ListingSINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it completed a reverse stock split on May 27, 2026, and requested a hearing before the Nasdaq Hearings Panel (the “Panel”), in response to a staff determination letter (the “Letter”) received on May 27, 2026, from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”). The Letter notified the Company that, due to the Company’s failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), Nasdaq has determined (the “Determination”) that Company’s securities will be scheduled for delisting from Nasdaq unless the Company requests an appeal of the Determination to a Panel.
NEW ERA ENERGY (NASDAQ:NUAI) DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds New Era Energy & Digital, Inc. Investors of the June 1st Deadline to Seek Lead Plaintiff RoleBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In New Era Energy (NUAI) To Contact Him Directly To Discuss Their Options
Shoptalk Connects Groceryshop and Shoptalk Fall, Announces Innovation WeekTwo cities, two flagship events. A combined 7,500 executives. A $250 ticket add-on gets attendees into both.
ATN International, Inc. to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 11, 2026 in New YorkBEVERLY, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- ATN International, Inc. (“ATN”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ATNI), a leading provider of digital infrastructure and communications services, today announced that management will participate in the 16th Annual East Coast IDEAS Investor Conference at The Westin New York at Times Square on June 11, 2026.
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with DiabetesDANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Afrezza® (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.
Antichi Cammini d’Italia: the Italia.it app and smart signage automatically interact with users along the five routesA network of 60 smart devices installed along the five itineraries, equipped with proximity technology, connects with the Italia.it app: users receive push notifications on their smartphones, giving them immediate access to maps and multimedia content. An integral part of the “Antichi Cammini d’Italia” project.
Syncron and TrueContext Help Manufacturers Turn Field Execution into Better Warranty DecisionsIntegration connects mobile field workflows with warranty operations to improve data quality, service performance, and operational efficiency
Karat Packaging to Participate in Wells Fargo 16th Annual Global Industrials & Materials ConferenceCHINO, Calif, May 29, 2026 (GLOBE NEWSWIRE) -- Karat Packaging Inc. (Nasdaq: KRT) (“Karat”), a specialty distributor and manufacturer of disposable foodservice products and related items, today announced that Chief Executive Officer, Alan Yu, and Chief Financial Officer, Jian Guo, will participate in a fireside chat at the Wells Fargo 16th Annual Industrials & Materials Conference on Thursday, June 11, 2026 at 12:45 pm CDT, taking place at the Loews Chicago Hotel. Management will conduct one-on-one meetings with investors during the conference.
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or “the Company”) (
NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SRAD Investors Have Opportunity to Lead Sportradar Group AG Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sportradar Group AG (“Sportradar” or “the Company”) (
NASDAQ: SRAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
CVLT Investors Have Opportunity to Lead Commvault Systems, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Commvault Systems, Inc. (“Commvault” or “the Company”) (
NASDAQ: CVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
GPK Investors Have Opportunity to Lead Graphic Packaging Holding Company Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Graphic Packaging Holding Company (“Graphic Packaging” or “the Company”) (
NYSE: GPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Ipsos announces the creation of an Advisory Board chaired by Eileen CampbellIpsos announces the creation of an Advisory Board chaired by Eileen Campbell
FSK Investors Have Opportunity to Lead FS KKR Capital Corp. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FS KKR Capital Corp. (“FSK” or “the Company”) (
NYSE: FSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
POET Investors Have Opportunity to Lead POET Technologies Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against POET Technologies Inc. (“POET” or “the Company”) (
NASDAQ: POET) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SES Investors Have Opportunity to Lead SES AI Corporation Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SES AI Corporation (“SES” or “the Company”) (
NYSE: SES) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
